Post Reply
9321-9340 of 10899
| bengster68 Senior |
Posted: 11-Dec-2007 12:20 |
 x 0  x 0 * Alert Admin |
Question: U did mentioned that de management of BIG (or someone sitting in there) has a brillant way to boost the unvalued shares up to its marks. Has this been done? Answer: Yes, its in the progress. There are 2 parts here in this method of bringing up BIG's valuation. But i feel BIG is being too greedy and doing trying to do Part 1 before doing Part 2. I feel they should go directly to Part 2 because i foresee Part 1 method has very little chance of success. Put it this way, "You may be clever but that doesn't mean others are stupid" and i feel BIG don't have enough good bargining power to close Part 1 successfully. Should just forget about Part 1 and go straight to Part 2. Part 2 itself is already very good move. However, if can close Part 1 first, then do Part 2, the effect will be double. If do Part 2 now, the opportunity to do Part 1 will be lost. |
I think BIG can succeed in achieving half of the deal under Part 1. Part 2 is very simple to do. Achieving half of Part 1 deal and proceed to do Part 2 can bring up BIG's valuation by 70cts per share.
I also expect some Japanese news to come in soon.
The "mother of all announcements" now will be USA news. Once this deal is done, see this stock cross above the all time high of $1.50. If this deal is done, BIG will no longer be pre-earnings company. BIG will represent the new era of DES with solid exponential profit growth.
thanks Mr Bengstar.........just sit back and enjoy the show....hold tight tight......
A02041315 your elephant sure can dances....
| bengster68 Senior |
Posted: 05-Dec-2007 18:27 |
| x 0 x 0 * Alert Admin |
You better watch out You better not cry You better not pout I'm telling you why Santa Claus is coming to town!!!    |
Give clue cannot give all in details mah........ There are shortists here also. They short and made the share price until this pitiful state. Even before CE this stock was trading above $1 from after IPO until before mid-2006. Too bad the impact not so huge as expected. 85cts to 95cts was the usual trading range before the sub-prime. This stock is currently still very undervalued. Verbal approval was given long ago and there was a CE meeting o 20/12/07 for several medical devices including Biomatrix. Also, Taxus Liberte just got their CE for diabetics a few days ago. I think both DESs had their CE panel on 20/12/07. Remember Taxus Liberte was the DES that Biomatrix beat last 2 months back? Restenosis rate of 0.7% VS 5.4%, thrombosis rate of 0% VS 4.4%. If they can give to BSX the CE, how can they don't give BIG? Cannot kelong until like that right?
Boston Scientific Stent Gets New EU Use
Friday December 21, 3:42 pm ET
NATICK, Mass. (AP) -- Boston Scientific Corp. said Friday its next-generation drug-coated stent received European Union approval for use in diabetics.
Company studies of more than 1,500 patients showed similar results for diabetic and non-diabetic patients implanted with its Taxus-Liberte stent. The tiny mesh-metal tubes are used to prop open arteries after they have been cleared of plaque. The drug coatings are designed to prevent scar tissue from growing over the stent, however recent studies have raised concerns they can actually lead to dangerous blood clots.
Boston Scientific is still awaiting approval for the Taxus-Liberte in the U.S., where a pending warning letter from the Food and Drug Administration has stalled approval of new devices from the company.
Competitor Medtronic is expected to gain FDA approval for its Endeavor drug-coated stent in the coming month, giving the company a jump-start in the U.S. market. Johnson & Johnson's Cypher and Boston Scientific's original Taxus stent are the only drug-coated stents currently available in the country.
Company studies of more than 1,500 patients showed similar results for diabetic and non-diabetic patients implanted with its Taxus-Liberte stent. The tiny mesh-metal tubes are used to prop open arteries after they have been cleared of plaque. The drug coatings are designed to prevent scar tissue from growing over the stent, however recent studies have raised concerns they can actually lead to dangerous blood clots.
|
Competitor Medtronic is expected to gain FDA approval for its Endeavor drug-coated stent in the coming month, giving the company a jump-start in the U.S. market. Johnson & Johnson's Cypher and Boston Scientific's original Taxus stent are the only drug-coated stents currently available in the country.
CHA CHA BO
BIG!!!!!!!!!!CHEONG!!!!!!!!!!!!AR!!!!!!!!!
SHA!!!!!!!!!!SHA!!!!!!!!!!!!!!!
Money already inside pocket.CHEERS!!!!!!!!!!!!!!!
Good luck BIG brothers
Mr Mani
Following the genie's advice here, I have been buying and selling stents in a BIG way heehee...
Lausk22... :)
Precisely... Always let your Genie be your guide... hehehe...
Mr Mani....my old pal...:)
To me: Sharejunction is a genie, occassionally unleashing some gems to be picked up and make me smile to the bank.
Lausk22... wo de lao peng you... :)
Losing is part and parcel of stock market play...
The 'trick' is to lose small when you lose...
And win big when you win...
But normally, people will win small and lose big...
"If they follow the teachings religiously, they will not be losing substantial amounts of money...
"
In other words, they will still lose...........
?